Mobidiag Signs New International Agreements for Distribution of its Amplidiag® and Novodiag® Diagnostic Solutions
29.10.2019 10:00:00 EET | Business Wire | Press release
Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has signed new exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with ALAB Ltd. for Poland and Ukraine, BIOgenetiX for Romania and Theranostica Ltd. for Israel.
Tuomas Tenkanen, CEO of Mobidiag, said “We are extremely pleased to have further expanded our commercial footprint into additional international territories. Our highly versatile and complementary Amplidiag® and Novodiag® diagnostic solutions continue to gain traction internationally. We are in ongoing discussions with several distribution partners in a range of international markets as customers look for fast, accurate and affordable diagnostic solutions to a wide range of infectious diseases.”
Gilda Cristea, Imports Manager of BIOgenetiX, comments “ It is a great opportunity for BIOgenetiX to collaborate with Mobidiag in Romania. The control of infections and the identification of antibiotic resistant pathogens are critical in all clinical environments. Mobidiag offers a diverse range of products that are easy to use, have great diagnostic precision and are affordable. These products are very important for the general management of patients and hospitals and we see them offering a great opportunity for the future.”
Amnon Hezkaya CEO of Theranostica, continues "We are really excited to start this partnership between Theranostica and Mobidiag. Mobidiag with its Novodiag® solution has the potential to be transformational for Israeli clinical laboratory customers as an affordable, fast sample to result system, which can test multiple targets at once.”
- Ends -
Notes to editors
About Mobidiag Ltd
Mobidiag is a revenue generating, fast growing molecular diagnostics company with complementary platform technologies that can meet the differing diagnostic needs for customers in multiple healthcare settings. Initially designed for ease of use and adapatability for large scale manufacturing, Mobidiag’s Amplidiag® and Novodiag® platforms provide a combination of high quality and affordability, allowing for widespread applicability for both mass screening and highly specific syndromic testing in multiple indications. The Company’s highly versatile product offering enables the broad application of molecular diagnostics to address the global challenge of antimicrobial resistance and other unmet diagnostic needs. Mobidiag’s intial focus has been on gastrointestinal diseases and superbugs, through direct sales and distributors, and is rapidly building a leading position in European markets.
Mobidiag has more than 100 staff and is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
About ALAB Ltd.
ALAB Ltd. based in Warsaw, Poland is a specialized company operating in the laboratory market in Poland and Ukraine. ALAB Ltd. is a member of ALAB GROUP including ALAB LABORATORIA – a key market player in routine and specialized diagnostics and ALAB PLUS – histopathology laboratory service. For 25 years ALAB Ltd. has been conducting commercial and service activities for public and private institutions. Its specialty is the comprehensive equipping of laboratory rooms in biotechnology, molecular biology, physico-chemical, microbiology and diagnostics.
About BIOgenetiX
BIOgenetiX is a distribution company for medical products in Romania. The company provides products and technical support for laboratories performing molecular biology diagnostic tests. BIOgenetiX addresses both state owned and private clinics, laboratories and hospitals. The company was established in 2009 and at the moment it is one of the most important Romanian companies in the field of medical products distribution. BIOgenetiX has a special program in the area of infections control and prevention. The company is focused on providing customers with more advanced technologies for molecular diagnostics and resistance genes identification.
Theranostica Ltd
Theranostica Ltd., established in 2010 is a leading Israeli distributor for innovative clinical diagnostics solutions from the United States, Europe and Asia. In the past nine years Theranostica has been succesful in bringing to the Israeli health system dozens of new technologies which helped to provide better medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005046/en/
Contact information
Johanna Sarapää, Marketing Communications
+358 10 2054 771
marketing@mobidiag.com
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Chris Welsh
T: +44 (0)203 709 5700
mobidiag@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3.9.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees. The equity awards were granted on September 1, 2026 and consisted of options to purchase an aggregate of 280,600 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 133,500 shares. The options have an exercise price per share equal to $13.24, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restr
Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®3.9.2026 23:30:00 EEST | Press release
Mainstay Medical Holdings plc today announced the publication of the two-year assessment results from the RESTORE randomized clinical trial of ReActiv8 for the treatment of intractable chronic low back pain. The data show continued improvements in back pain-related disability, pain and quality of life in the ReActiv8 treatment group, and improvements after one year of ReActiv8 therapy in the crossover group that were indistinguishable from the improvements shown by the treatment group at their one-year assessment. The results were published in The Spine Journal, and the article is available free of charge here: https://doi.org/10.1016/j.spinee.2026.07.006. The study included 203 patients, with 99 randomized into the treatment arm and 104 randomized into the control arm. Patient-reported outcomes were collected at regular intervals to the one-year primary endpoint assessment, at which time the patients in the control arm were offered implantation with the ReActiv8 system. Eighty-three p
Lenovo Advances Hybrid AI Across New Personal and Enterprise Technology3.9.2026 19:00:00 EEST | Press release
Today at Lenovo™ Innovation World during IFA 2026, Lenovo unveiled a new portfolio of personal and enterprise technology, showing how its Hybrid AI strategy is moving from vision to practical experiences across devices, infrastructure, services, and the everyday moments that connect them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903555953/en/ Lenovo Innovation World at IFA 2026 The announcements bring together Lenovo’s “one personal AI, multiple devices” approach with enterprise technology that helps organizations turn data into insights and value. They span personal AI across PCs, smartphones, tablets, and wearables; creator and consumer devices that adapt to different ways of working and expressing ideas; and business technology built for AI-enabled productivity, collaboration, security, and scale. Lenovo also demonstrated how design and form factor remain central to making technology more useful: from high-perfor
Kaltura and Verimatrix Partner to Strengthen Security for OTT and Cloud TV Services3.9.2026 18:45:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903384589/en/ Kaltura (Nasdaq: KLTR), the Agentic Digital Experience company, and Verimatrix (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced a strategic partnership designed to provide enhanced protection for OTT and Cloud TV services. The partnership brings together Kaltura's scalable Cloud TV platform and Verimatrix's Digital Rights Management (DRM) and security capabilities. The joint solution, as part of Kaltura’s Marketplace, helps Telco’s, broadcasters, and media companies securely deliver premium live and on-demand content across a wide range of devices and operating systems. Demand for advanced content protection has grown, and Kaltura's Cloud TV footprint has expanded across Telco’s, operators, broadcasters, and media companies. Partnering with Verimatrix, a recognized leader in content pro
Bahrain Signs its Participation Contract for Expo 2030 Riyadh3.9.2026 18:45:00 EEST | Press release
The Kingdom of Bahrain has signed its Participation Contract for Expo 2030 Riyadh, marking a new phase in preparations for its participation in the World Expo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903144412/en/ His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President of the Bahrain Authority for Culture and Antiquities, and Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, at the ceremony. The agreement provides the formal framework for Bahrain’s participation in Expo 2030 Riyadh, enabling preparations to advance across the key organizational and operational aspects of its presence throughout the six-month event, including the development of its pavilion, programmes and visitor experiences. The Participation Contract was signed in Bahrain by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh, on behalf of Expo 2030 Riyadh, and His Excellency Sheikh Khalifa bin Ahmed Al Khalifa, President
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom